Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
24 recherche sur le mot-clé 'clinical trial'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Brief Report: Hyperbaric Oxygen Therapy (HBOT) in Children with Autism Spectrum Disorder: A Clinical Trial / Stephen BENT in Journal of Autism and Developmental Disorders, 42-6 (June 2012)
[article]
Titre : Brief Report: Hyperbaric Oxygen Therapy (HBOT) in Children with Autism Spectrum Disorder: A Clinical Trial Type de document : Texte imprimé et/ou numérique Auteurs : Stephen BENT, Auteur ; Kiah BERTOGLIO, Auteur ; Paul ASHWOOD, Auteur ; Edward NEMETH, Auteur ; Robert L. HENDREN, Auteur Année de publication : 2012 Article en page(s) : p.1127-1132 Langues : Anglais (eng) Mots-clés : Autism Clinical trial Alternative therapy Index. décimale : PER Périodiques Résumé : We sought to determine whether HBOT leads to parental reported behavioral changes and alterations in cytokines in children with ASD. Ten children completed 80 sessions of HBOT and all improved by 2 points on the clinician-rated CGI-I scale (much improved) as well as several parent-completed measures of behavior. The lack of a control group limits the ability to determine if improvements were related to HBOT. Enrolled children did not exhibit abnormal cytokine levels at baseline and no significant changes in mean cytokine levels were observed. Although this study was limited by the small sample size and by the variable nature of cytokines, we found no evidence that HBOT affects cytokine levels or that cytokine levels were associated with behavioral changes. En ligne : http://dx.doi.org/10.1007/s10803-011-1337-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=156
in Journal of Autism and Developmental Disorders > 42-6 (June 2012) . - p.1127-1132[article] Brief Report: Hyperbaric Oxygen Therapy (HBOT) in Children with Autism Spectrum Disorder: A Clinical Trial [Texte imprimé et/ou numérique] / Stephen BENT, Auteur ; Kiah BERTOGLIO, Auteur ; Paul ASHWOOD, Auteur ; Edward NEMETH, Auteur ; Robert L. HENDREN, Auteur . - 2012 . - p.1127-1132.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 42-6 (June 2012) . - p.1127-1132
Mots-clés : Autism Clinical trial Alternative therapy Index. décimale : PER Périodiques Résumé : We sought to determine whether HBOT leads to parental reported behavioral changes and alterations in cytokines in children with ASD. Ten children completed 80 sessions of HBOT and all improved by 2 points on the clinician-rated CGI-I scale (much improved) as well as several parent-completed measures of behavior. The lack of a control group limits the ability to determine if improvements were related to HBOT. Enrolled children did not exhibit abnormal cytokine levels at baseline and no significant changes in mean cytokine levels were observed. Although this study was limited by the small sample size and by the variable nature of cytokines, we found no evidence that HBOT affects cytokine levels or that cytokine levels were associated with behavioral changes. En ligne : http://dx.doi.org/10.1007/s10803-011-1337-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=156 Preliminary analysis of a clinical trial of children with autism spectrum disorder treated with DHA-rich marine Schizochytrium sp. oil and multi-vitamin/mineral complex / Maria Aparecida Baptista de OLIVEIRA ; Fernando Augusto Lima MARSON ; Juliana Mozer SCIANI in Research in Autism Spectrum Disorders, 109 (November 2023)
[article]
Titre : Preliminary analysis of a clinical trial of children with autism spectrum disorder treated with DHA-rich marine Schizochytrium sp. oil and multi-vitamin/mineral complex Type de document : Texte imprimé et/ou numérique Auteurs : Maria Aparecida Baptista de OLIVEIRA, Auteur ; Fernando Augusto Lima MARSON, Auteur ; Juliana Mozer SCIANI, Auteur Article en page(s) : 102282 Langues : Anglais (eng) Mots-clés : Autism Children Docosahexaenoic acid Multi-vitamin & mineral complex Clinical trial Index. décimale : PER Périodiques Résumé : Background Autism spectrum disorder (ASD) is a syndrome characterized by alterations in social interaction and communication, frequently associated with stereotyped patterns, such as repetitive behavior. Inflammation and oxidative stress are frequently observed in patients, and natural products that control these aspects can be an alternative for ASD treatment. Method: In this prospective case series study, we administered in 2-12 years-old children (n = 12) with severe ASD a commercial extract of marine Schizochytrium sp. oil, composed by 200 mg DHA and 2 mg eicosapentaenoic acid, associated to a multi-vitamin/mineral complex, daily for 12 weeks. Patients were evaluated by Childhood Autism Rating Scale (CARS) and Adaptive Behavior Assessment System Third Edition (ABAS-3) scales before and after the treatment, and had the urine analyzed. Results: Values obtained from CARS, general adaptive composite and social domains from ABAS-3 were statistically different after treatment. Although not statistically significant, conceptual and practical domains from ABAS-3 had the score increased in several patients after the intervention. Among these domains, communication and visual contact improved in all patients, and vocabulary, interaction, feeding, and food selectivity were enhanced in some of them. The total antioxidant capacity in urine increased after treatment, as well as some metabolites, like amino acids, which were exclusive in all patient?s urine after the administration of the product. Conclusions: These preliminary data show that the continuous use of marine Schizochytrium sp. oil and multi-vitamin/mineral complex can help control characteristic symptoms of ASD in children. En ligne : https://doi.org/10.1016/j.rasd.2023.102282 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=518
in Research in Autism Spectrum Disorders > 109 (November 2023) . - 102282[article] Preliminary analysis of a clinical trial of children with autism spectrum disorder treated with DHA-rich marine Schizochytrium sp. oil and multi-vitamin/mineral complex [Texte imprimé et/ou numérique] / Maria Aparecida Baptista de OLIVEIRA, Auteur ; Fernando Augusto Lima MARSON, Auteur ; Juliana Mozer SCIANI, Auteur . - 102282.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 109 (November 2023) . - 102282
Mots-clés : Autism Children Docosahexaenoic acid Multi-vitamin & mineral complex Clinical trial Index. décimale : PER Périodiques Résumé : Background Autism spectrum disorder (ASD) is a syndrome characterized by alterations in social interaction and communication, frequently associated with stereotyped patterns, such as repetitive behavior. Inflammation and oxidative stress are frequently observed in patients, and natural products that control these aspects can be an alternative for ASD treatment. Method: In this prospective case series study, we administered in 2-12 years-old children (n = 12) with severe ASD a commercial extract of marine Schizochytrium sp. oil, composed by 200 mg DHA and 2 mg eicosapentaenoic acid, associated to a multi-vitamin/mineral complex, daily for 12 weeks. Patients were evaluated by Childhood Autism Rating Scale (CARS) and Adaptive Behavior Assessment System Third Edition (ABAS-3) scales before and after the treatment, and had the urine analyzed. Results: Values obtained from CARS, general adaptive composite and social domains from ABAS-3 were statistically different after treatment. Although not statistically significant, conceptual and practical domains from ABAS-3 had the score increased in several patients after the intervention. Among these domains, communication and visual contact improved in all patients, and vocabulary, interaction, feeding, and food selectivity were enhanced in some of them. The total antioxidant capacity in urine increased after treatment, as well as some metabolites, like amino acids, which were exclusive in all patient?s urine after the administration of the product. Conclusions: These preliminary data show that the continuous use of marine Schizochytrium sp. oil and multi-vitamin/mineral complex can help control characteristic symptoms of ASD in children. En ligne : https://doi.org/10.1016/j.rasd.2023.102282 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=518 The Feasibility of Magnetic Resonance Imaging in a Non-Selective Comprehensive Clinical Trial in Pediatric Autism Spectrum Disorder / Marilena M. DEMAYO in Journal of Autism and Developmental Disorders, 52-3 (March 2022)
[article]
Titre : The Feasibility of Magnetic Resonance Imaging in a Non-Selective Comprehensive Clinical Trial in Pediatric Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Marilena M. DEMAYO, Auteur ; I. POKORSKI, Auteur ; Y. J. C. SONG, Auteur ; R. THAPA, Auteur ; S. PATEL, Auteur ; Zahava AMBARCHI, Auteur ; D. SOLIGO, Auteur ; I. SADELI, Auteur ; E. E. THOMAS, Auteur ; I. B. HICKIE, Auteur ; A. J. GUASTELLA, Auteur Article en page(s) : p.1211-1222 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/diagnostic imaging Brain Child Child, Preschool Feasibility Studies Humans Magnetic Resonance Imaging/methods Autism spectrum disorders Biomarkers Brain function Brain structure Clinical trial Interventions–pharmacologic Magnetic resonance imaging Neuroimaging Pre-school children School-age children Index. décimale : PER Périodiques Résumé : There is an increasing interest in using magnetic resonance imaging (MRI) as a tool for precision medicine in autism spectrum disorder (ASD). This study investigated the feasibility of MRI scanning in a large comprehensive, inclusive and test heavy clinical trial for children (aged 3-12 years) with ASD, without functioning constraints for participation. Of the 71 participants enrolled who consented to the MRI, 24 participants (38%) successfully completed an MRI scan at baseline along with other assessments. This scanning followed a familiarization procedure at two preceding visits. At post-treatment, 21 participants successfully completed the MRI scan. This study highlights the challenge of completing MRI assessments in ASD populations when conducted as one of a number of tests in a clinical trial. En ligne : http://dx.doi.org/10.1007/s10803-021-05028-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=455
in Journal of Autism and Developmental Disorders > 52-3 (March 2022) . - p.1211-1222[article] The Feasibility of Magnetic Resonance Imaging in a Non-Selective Comprehensive Clinical Trial in Pediatric Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Marilena M. DEMAYO, Auteur ; I. POKORSKI, Auteur ; Y. J. C. SONG, Auteur ; R. THAPA, Auteur ; S. PATEL, Auteur ; Zahava AMBARCHI, Auteur ; D. SOLIGO, Auteur ; I. SADELI, Auteur ; E. E. THOMAS, Auteur ; I. B. HICKIE, Auteur ; A. J. GUASTELLA, Auteur . - p.1211-1222.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 52-3 (March 2022) . - p.1211-1222
Mots-clés : Autism Spectrum Disorder/diagnostic imaging Brain Child Child, Preschool Feasibility Studies Humans Magnetic Resonance Imaging/methods Autism spectrum disorders Biomarkers Brain function Brain structure Clinical trial Interventions–pharmacologic Magnetic resonance imaging Neuroimaging Pre-school children School-age children Index. décimale : PER Périodiques Résumé : There is an increasing interest in using magnetic resonance imaging (MRI) as a tool for precision medicine in autism spectrum disorder (ASD). This study investigated the feasibility of MRI scanning in a large comprehensive, inclusive and test heavy clinical trial for children (aged 3-12 years) with ASD, without functioning constraints for participation. Of the 71 participants enrolled who consented to the MRI, 24 participants (38%) successfully completed an MRI scan at baseline along with other assessments. This scanning followed a familiarization procedure at two preceding visits. At post-treatment, 21 participants successfully completed the MRI scan. This study highlights the challenge of completing MRI assessments in ASD populations when conducted as one of a number of tests in a clinical trial. En ligne : http://dx.doi.org/10.1007/s10803-021-05028-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=455 A pilot open-label trial of minocycline in patients with autism and regressive features / Carlos A. PARDO in Journal of Neurodevelopmental Disorders, 5-1 (December 2013)
[article]
Titre : A pilot open-label trial of minocycline in patients with autism and regressive features Type de document : Texte imprimé et/ou numérique Auteurs : Carlos A. PARDO, Auteur ; A. BUCKLEY, Auteur ; A. THURM, Auteur ; L. C. LEE, Auteur ; A. AZHAGIRI, Auteur ; D. M. NEVILLE, Auteur ; Susan E. SWEDO, Auteur Article en page(s) : p.9 Langues : Anglais (eng) Mots-clés : Autism Bdnf Chemokines Clinical trial Cytokines Metalloproteinases Microglia Minocycline Neuroinflammation Neurotrophins Index. décimale : PER Périodiques Résumé : BACKGROUND: Minocycline is a tetracycline derivative that readily crosses the blood brain barrier and appears to have beneficial effects on neuroinflammation, microglial activation and neuroprotection in a variety of neurological disorders. Both microglial activation and neuroinflammation have been reported to be associated with autism. The study was designed to evaluate the effects of minocycline treatment on markers of neuroinflammation and autism symptomatology in children with autism and a history of developmental regression. METHODS: Eleven children were enrolled in an open-label trial of six months of minocycline (1.4 mg/kg). Ten children completed the trial. Behavioral measures were collected and cerebrospinal fluid (CSF), serum and plasma were obtained before and at the end of minocycline treatment and were analyzed for markers of neuroinflammation. RESULTS: Clinical improvements were negligible. The laboratory assays demonstrated significant changes in the expression profile of the truncated form of brain derived neurotrophic factor (BDNF) (P = 0.042) and hepatic growth factor (HGF) (P = 0.028) in CSF. In serum, the ratio of the truncated BDNF form and alpha-2 macroglobulin (alpha-2 M), was also significantly lower (P = 0.028) while the mature BDNF/alpha-2 M ratio revealed no difference following treatment. Only the chemokine CXCL8 (IL-8) was significantly different (P = 0.047) in serum while no significant changes were observed in CSF or serum in chemokines such as CCL2 (MCP-1) or cytokines such as TNF-alpha, CD40L, IL-6, IFN-gamma and IL-1beta when pre- and post-treatment levels of these proteins were compared. No significant pre- and post-treatment changes were seen in the profiles of plasma metalloproteinases, putative targets of the effects of minocycline. CONCLUSIONS: Changes in the pre- and post-treatment profiles of BDNF in CSF and blood, HGF in CSF and CXCL8 (IL-8) in serum, suggest that minocycline may have effects in the CNS by modulating the production of neurotrophic growth factors. However, in this small group of children, no clinical improvements were observed during or after the six months of minocycline administration. TRIAL REGISTRATION: NCT00409747. En ligne : http://dx.doi.org/10.1186/1866-1955-5-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=345
in Journal of Neurodevelopmental Disorders > 5-1 (December 2013) . - p.9[article] A pilot open-label trial of minocycline in patients with autism and regressive features [Texte imprimé et/ou numérique] / Carlos A. PARDO, Auteur ; A. BUCKLEY, Auteur ; A. THURM, Auteur ; L. C. LEE, Auteur ; A. AZHAGIRI, Auteur ; D. M. NEVILLE, Auteur ; Susan E. SWEDO, Auteur . - p.9.
Langues : Anglais (eng)
in Journal of Neurodevelopmental Disorders > 5-1 (December 2013) . - p.9
Mots-clés : Autism Bdnf Chemokines Clinical trial Cytokines Metalloproteinases Microglia Minocycline Neuroinflammation Neurotrophins Index. décimale : PER Périodiques Résumé : BACKGROUND: Minocycline is a tetracycline derivative that readily crosses the blood brain barrier and appears to have beneficial effects on neuroinflammation, microglial activation and neuroprotection in a variety of neurological disorders. Both microglial activation and neuroinflammation have been reported to be associated with autism. The study was designed to evaluate the effects of minocycline treatment on markers of neuroinflammation and autism symptomatology in children with autism and a history of developmental regression. METHODS: Eleven children were enrolled in an open-label trial of six months of minocycline (1.4 mg/kg). Ten children completed the trial. Behavioral measures were collected and cerebrospinal fluid (CSF), serum and plasma were obtained before and at the end of minocycline treatment and were analyzed for markers of neuroinflammation. RESULTS: Clinical improvements were negligible. The laboratory assays demonstrated significant changes in the expression profile of the truncated form of brain derived neurotrophic factor (BDNF) (P = 0.042) and hepatic growth factor (HGF) (P = 0.028) in CSF. In serum, the ratio of the truncated BDNF form and alpha-2 macroglobulin (alpha-2 M), was also significantly lower (P = 0.028) while the mature BDNF/alpha-2 M ratio revealed no difference following treatment. Only the chemokine CXCL8 (IL-8) was significantly different (P = 0.047) in serum while no significant changes were observed in CSF or serum in chemokines such as CCL2 (MCP-1) or cytokines such as TNF-alpha, CD40L, IL-6, IFN-gamma and IL-1beta when pre- and post-treatment levels of these proteins were compared. No significant pre- and post-treatment changes were seen in the profiles of plasma metalloproteinases, putative targets of the effects of minocycline. CONCLUSIONS: Changes in the pre- and post-treatment profiles of BDNF in CSF and blood, HGF in CSF and CXCL8 (IL-8) in serum, suggest that minocycline may have effects in the CNS by modulating the production of neurotrophic growth factors. However, in this small group of children, no clinical improvements were observed during or after the six months of minocycline administration. TRIAL REGISTRATION: NCT00409747. En ligne : http://dx.doi.org/10.1186/1866-1955-5-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=345 A randomized controlled trial into the effects of probiotics on electroencephalography in preschoolers with autism / Lucia BILLECI in Autism, 27-1 (January 2023)
[article]
Titre : A randomized controlled trial into the effects of probiotics on electroencephalography in preschoolers with autism Type de document : Texte imprimé et/ou numérique Auteurs : Lucia BILLECI, Auteur ; Alejandro Luis CALLARA, Auteur ; Letizia GUIDUCCI, Auteur ; Margherita PROSPERI, Auteur ; Maria Aurora MORALES, Auteur ; Sara CALDERONI, Auteur ; Filippo MURATORI, Auteur ; Elisa SANTOCCHI, Auteur Article en page(s) : p.117-132 Langues : Anglais (eng) Mots-clés : autism spectrum disorder clinical trial EEG preschoolers probiotics Index. décimale : PER Périodiques Résumé : Previous studies suggest that autism spectrum disorders are characterized by alterations in the microbiota-gut-brain axis. Probiotics may modify the composition and the functionality of the gut microbiota of autism spectrum disorder individuals, with possible cascading effects on brain function. In this study, we analyzed possible brain modifications induced by the administration of probiotics in 46 children with autism spectrum disorder using electroencephalography. A randomized 6-month controlled trial was performed. In subjects treated with probiotics, we observed a decrease of power in frontopolar regions in beta and gamma bands, and increased coherence in the same bands together with a shift in frontal asymmetry, which suggests a modification toward a typical brain activity. Electroencephalography measures were significantly correlated with clinical and biochemical measures. These findings support the importance of further investigations on probiotics’ benefits in autism spectrum disorder to better elucidate mechanistic links between probiotics supplementation and changes in brain activity. Lay abstract This study investigates the effects of a probiotic on preschoolers’ brain electrical activity with autism spectrum disorder. Autism is a disorder with an increasing prevalence characterized by an enormous individual, family, and social cost. Although the etiology of autism spectrum disorder is unknown, an interaction between genetic and environmental factors is implicated, converging in altered brain synaptogenesis and, therefore, connectivity. Besides deepening the knowledge on the resting brain electrical activity that characterizes this disorder, this study allows analyzing the positive central effects of a 6-month therapy with a probiotic through a randomized, double-blind placebo-controlled study and the correlations between electroencephalography activity and biochemical and clinical parameters. In subjects treated with probiotics, we observed a decrease of power in frontopolar regions in beta and gamma bands, and increased coherence in the same bands together with a shift in frontal asymmetry, which suggests a modification toward a typical brain activity. Electroencephalography measures were significantly correlated with clinical and biochemical measures. These findings support the importance of further investigations on probiotics’ benefits in autism spectrum disorder to better elucidate mechanistic links between probiotics supplementation and changes in brain activity. En ligne : http://dx.doi.org/10.1177/13623613221082710 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=491
in Autism > 27-1 (January 2023) . - p.117-132[article] A randomized controlled trial into the effects of probiotics on electroencephalography in preschoolers with autism [Texte imprimé et/ou numérique] / Lucia BILLECI, Auteur ; Alejandro Luis CALLARA, Auteur ; Letizia GUIDUCCI, Auteur ; Margherita PROSPERI, Auteur ; Maria Aurora MORALES, Auteur ; Sara CALDERONI, Auteur ; Filippo MURATORI, Auteur ; Elisa SANTOCCHI, Auteur . - p.117-132.
Langues : Anglais (eng)
in Autism > 27-1 (January 2023) . - p.117-132
Mots-clés : autism spectrum disorder clinical trial EEG preschoolers probiotics Index. décimale : PER Périodiques Résumé : Previous studies suggest that autism spectrum disorders are characterized by alterations in the microbiota-gut-brain axis. Probiotics may modify the composition and the functionality of the gut microbiota of autism spectrum disorder individuals, with possible cascading effects on brain function. In this study, we analyzed possible brain modifications induced by the administration of probiotics in 46 children with autism spectrum disorder using electroencephalography. A randomized 6-month controlled trial was performed. In subjects treated with probiotics, we observed a decrease of power in frontopolar regions in beta and gamma bands, and increased coherence in the same bands together with a shift in frontal asymmetry, which suggests a modification toward a typical brain activity. Electroencephalography measures were significantly correlated with clinical and biochemical measures. These findings support the importance of further investigations on probiotics’ benefits in autism spectrum disorder to better elucidate mechanistic links between probiotics supplementation and changes in brain activity. Lay abstract This study investigates the effects of a probiotic on preschoolers’ brain electrical activity with autism spectrum disorder. Autism is a disorder with an increasing prevalence characterized by an enormous individual, family, and social cost. Although the etiology of autism spectrum disorder is unknown, an interaction between genetic and environmental factors is implicated, converging in altered brain synaptogenesis and, therefore, connectivity. Besides deepening the knowledge on the resting brain electrical activity that characterizes this disorder, this study allows analyzing the positive central effects of a 6-month therapy with a probiotic through a randomized, double-blind placebo-controlled study and the correlations between electroencephalography activity and biochemical and clinical parameters. In subjects treated with probiotics, we observed a decrease of power in frontopolar regions in beta and gamma bands, and increased coherence in the same bands together with a shift in frontal asymmetry, which suggests a modification toward a typical brain activity. Electroencephalography measures were significantly correlated with clinical and biochemical measures. These findings support the importance of further investigations on probiotics’ benefits in autism spectrum disorder to better elucidate mechanistic links between probiotics supplementation and changes in brain activity. En ligne : http://dx.doi.org/10.1177/13623613221082710 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=491 Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder / Andrew W. ZIMMERMAN in Molecular Autism, 12 (2021)
PermalinkRandomized controlled trial of vitamin D supplementation in children with autism spectrum disorder / Khaled SAAD in Journal of Child Psychology and Psychiatry, 59-1 (January 2018)
PermalinkA randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome / A. LIGSAY in Journal of Neurodevelopmental Disorders, 9-1 (December 2017)
PermalinkErratum to: Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes / Beth A. MALOW in Journal of Autism and Developmental Disorders, 42-8 (August 2012)
PermalinkFamily-focused cognitive behavioral treatment for depressed adolescents in suicidal crisis with co-occurring risk factors: a randomized trial / C. ESPOSITO-SMYTHERS in Journal of Child Psychology and Psychiatry, 60-10 (October 2019)
Permalink